The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.
 
Joe Y. Chang
Stock and Other Ownership Interests - Global Advisory Board Medi-Globe
Research Funding - Bristol-Myers Squibb (Inst)
 
Lei Feng
No Relationships to Disclose
 
Steven H. Lin
Honoraria - AstraZeneca/MedImmune; ProCure; US Oncology
Research Funding - Genentech/Roche; Hitachi Chemical; Peregrine Pharmaceuticals; STCube Pharmaceuticals Inc.
Travel, Accommodations, Expenses - STCube Pharmaceuticals Inc.; US Oncology
 
James William Welsh
No Relationships to Disclose
 
Mara Antonoff
No Relationships to Disclose
 
Daniel Richard Gomez
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Merck
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Genentech; Medivation; Novartis; Oncomed; Synta
Research Funding - AstraZeneca (Inst)